THREE groundbreaking papers published in the New England Journal of Medicine, from a team of Monash University researchers in Melbourne, reveal the results from a seven-year study of the benefits and risks of a low daily dose of aspirin to the lives of people aged more than 70 years.
Results were similar to another recently released paper evaluating the role of aspirin in otherwise healthy adults without a history of heart disease (PD 32 Aug), where cardiovascular event rates were reduced by aspirin (-12%) but risk of major bleed was up 29%.
In these studies, serious bleeding among the aspirin-takers (3.8%) was significantly greater than in the placebo group (2.8%).
Monash University Department of Epidemiology and Preventive Medicine head and principal investigator Professor John McNeil (pictured) said the study showed no overall benefit to offset the risk of bleeding.
See more at monash.edu.
The above article was sent to subscribers in Pharmacy Daily's issue from 18 Sep 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 18 Sep 18
